United States · FDA National Drug Code directory
DARIFENACIN
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 62332-223_0f406336-e614-4427-89c7-bd26d3792590
- Product NDC
- 62332-223
- Form
- TABLET, EXTENDED RELEASE
- Composition / generic term
- DARIFENACIN
- Labeler
- Alembic Pharmaceuticals Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20171212
- Source listing expiry
- 20261231
Source-listed ingredients
- DARIFENACIN HYDROBROMIDE — 7.5 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 8 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (62332-223-08) · 62332-223-08
- 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (62332-223-30) · 62332-223-30
- 90 TABLET, EXTENDED RELEASE in 1 BOTTLE (62332-223-90) · 62332-223-90
- 1000 TABLET, EXTENDED RELEASE in 1 BOTTLE (62332-223-91) · 62332-223-91
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →